GlassScriptPhysician profile
Ian D Kleinhen
NPI 1013916808
$1,559.38
in general payments reported to CMS, 2019-2025
12 companies · $350 in 2025
The $350 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.14 · 2020: $71.33 · 2021: $358 · 2022: $102 · 2023: $199 · 2024: $462 · 2025: $350.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,007 · Education: $3.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,006.62 |
| Education | $3.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $842.93 | 2020-2025 | Airsupra, Bevespi Aerosphere, Breztri |
| Baxter Healthcare | $144.73 | 2023-2025 | Hillrom - Cardiac Ambulatory Monitor |
| Novo Nordisk INC | $123.86 | 2019-2024 | Ozempic, Rybelsus |
| Amgen INC. | $121.01 | 2024-2025 | Repatha, Repatha |
| Lilly USA, LLC | $92.34 | 2021-2024 | Mounjaro, Zepbound |
| Exact Sciences Corporation | $59.33 | 2023-2024 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $52.93 | 2021-2022 | |
| Abbott Laboratories | $32.35 | 2021 | |
| Glaxosmithkline, LLC. | $26.39 | 2023 | Trelegy Ellipta |
| Halozyme INC | $22.80 | 2023 | |
| Actelion Pharmaceuticals US, INC. | $21.15 | 2024 | Opsumit, Uptravi |
| Pfizer INC. | $19.56 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ian Kleinhen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.